IDH2 and acute myeloid leukemia: In a phase Ib/II clinical trial, Enasidenib was evaluated in 101 newly diagnosed IDH2-mutated AML patients not eligible for standard induction chemotherapy, the treatment based on Enasidenib plus Azacitidine (two-thirds of patients), or Azacitidine alone (one-third of patients) [55].